HRR References

Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res. 2001;477(1-2):131-153. doi:10.1016/s0027-5107(01)00115-4.
Thacker J. Homologous Recombination Repair. In: Schwab M, ed. Encyclopedia of Cancer. Springer; 2011:1725-1729. doi:10.1007/978-3-642-16483-5_2801.
Krajewska M, Fehrmann RSN, de Vries EGE, van Vugt MATM. Regulators of homologous recombination repair as novel targets for cancer treatment. Frontiers in Genetics. 2015;6. www.frontiersin.org/articles/10.3389/fgene.2015.00096. Accessed September 26, 2022.
Pellegrino B, Musolino A, Llop-Guevara A, et al. Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. Transl Oncol. 2020;13(2):410-422. doi:10.1016/j.tranon.2019.10.010.
Chen J, Huang T, Liu M, et al. The prognostic value of HRD mutations in liver cancer. J Clin Oncol. 2020;38(15_suppl):e13546-e13546. doi:10.1200/JCO.2020.38.15_suppl.e13546.
Pathogenic Germline Mutations Far More Common in Lung Cancer Than Previously Thought. ASCO Daily News. https://dailynews.ascopubs.org/do/10.1200/ADN.22.201096/full. Accessed September 26, 2022.
Vergote I, González-Martín A, Ray-Coquard I, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology. 2022;33(3):276-287. doi:10.1016/j.annonc.2021.11.013.
Scott RJ, Mehta A, Macedo GS, et al. Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. Oncotarget. 2021;12(16):1600-1614. doi:10.18632/oncotarget.28015.

Recent News

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

Conference Coverage

Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

Results from a phase 2 study...

09/10/2024

Oncology

Conference Coverage

Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.

According to results from the...

09/10/2024

Oncology

Conference Coverage

Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

According to results from the...

09/10/2024

Oncology

Conference Coverage

Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer

09/09/2024

Allison Casey ;

Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.

Ivonescimab showed a clinically...

09/09/2024

Oncology

Conference Coverage

Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

According to phase 1/2 study...

09/09/2024

Oncology